TLR4 and psoriasis: It is thought that phosphatidylglycerol reduces inflammation and improves psoriasiform skin lesions by decreasing inflammatory mediator production induced by TLR2 and TLR4 activation in response to danger-associated molecular patterns, such as anti-microbial peptides [24], many of which are elevated in psoriasis and mouse models of the disease [31,51].